STOCK TITAN
  1. Home
  2. News
  3. BIIB

Biogen Inc - BIIB STOCK NEWS

IMPACT
SENTIMENT
BIIB : Nasdaq
Biogen Announces Peer-Reviewed Publication of ADUHELM® Phase 3 EMERGE and ENGAGE Data in The Journal of Prevention of Alzheimer’s Disease
clinical trial
IMPACT
SENTIMENT
BIIB : Nasdaq
Long-Term Phase 3 Data Show ADUHELM® Continues to Reduce Underlying Pathologies of Alzheimer’s Disease in Patients Treated for More Than Two Years
clinical trial
IMPACT
SENTIMENT
BIIB : Nasdaq
Biogen and Eisai amend collaboration agreements on Alzheimer’s disease treatments
IMPACT
SENTIMENT
BIIB : Nasdaq
Biogen Announces New Updates Across its SMA Research Program at 2022 MDA Conference
IMPACT
SENTIMENT
BIIB : Nasdaq
Biogen to Present New Research at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD 2022)
conferences
IMPACT
SENTIMENT
BIIB : Nasdaq
EISAI INITIATES SUBMISSION OF APPLICATION DATA UNDER THE PRIOR ASSESSMENT CONSULTATION SYSTEM IN JAPAN WITH THE AIM OF OBTAINING EARLY APPROVAL FOR INVESTIGATIONAL ANTI-AMYLOID BETA PROTOFIBRIL ANTIBODY LECANEMAB
IMPACT
SENTIMENT
SAGE : Nasdaq BIIB : Nasdaq
Sage Therapeutics and Biogen Announce the Phase 3 CORAL Study Met its Primary and Key Secondary Endpoints - Comparing Zuranolone 50 mg Co-initiated with Standard of Care Antidepressant vs. Standard of Care Co-initiated with Placebo in People with MDD
clinical trial
IMPACT
SENTIMENT
BIIB : Nasdaq
Biogen and Xbrane Announce Commercialization and License Agreement for Proposed Biosimilar Referencing CIMZIA® (Certolizumab pegol) with the Potential to Treat Rheumatoid Arthritis
IMPACT
SENTIMENT
BIIB : Nasdaq
Biogen Exercises Option to Participate in the Development and Commercialization of a Late-Stage Bispecific Antibody
conferences
IMPACT
SENTIMENT
BIIB : Nasdaq
Biogen Announces Nancy Leaming and Brian Posner to Retire from Board of Directors
management
Stock BIIB logo
Biogen Inc

Nasdaq:BIIB

BIIB Rankings

#421 Ranked by Market Cap
#3170 Ranked by Stock Gains
N/A Ranked by Dividends

BIIB Stock Data

Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Cambridge

About BIIB

through cutting-edge science and medicine, biogen discovers, develops and delivers innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases. founded in 1978, biogen is a pioneer in biotechnology and today the company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including alzheimer’s disease, parkinson’s disease and amyotrophic lateral sclerosis. biogen also manufactures and commercializes biosimilars of advanced biologics. with approximately 7000 people worldwide, we are truly a global organization, headquartered in cambridge, massachusetts, which is also home to our research operations. our international headquarters are based in zug, switzerland and we have world-class manufacturing facilities in north carolina and denmark. we offer therapies globally through direct affili